20 search results for: remission

expert video

What Could Remission Mean in AD?

1 min

Dermatology

Dr. Simpson explores the concept of remission in AD, focusing on minimal disease activity and long-term remission, discussing how disease modification in AD can impact the course of the disease and its associated comorbidities.

Is 1 year an appropriate timeframe for deciding if a patient has achieved <b>remission</b> in CRSwNP?

expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

5 min

Rhinology

Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission

Podcast

ADVENT On Air | Remission in CRSwNP

19 min

Rhinology

Prof. Peter Hellings and Dr. Stella Lee discuss the concept of remission for patients with chronic rhinosinusitis with nasal polyps.

expert video

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

3 min

Rhinology

Prof. Peter Hellings highlights the EPOS/EUFOREA 2024 definition of remission and calls for an elevation of treatment goals in CRSwNP.

expert video

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

20 min

Rhinology

Prof. Peter Hellings and Prof. Eugenio De Corso discuss viewpoints on the emerging definitions of disease remission in CRSwNP.

What treatments may be needed to achieve <b>remission</b>? And In what percentage of patients could <b>remission</b> be a target?

expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

5 min

Rhinology

Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in <b>Remission</b> if the Patient has an Impaired Sense of Smell?

expert video

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

5 min

Rhinology

Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.

expert video

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

10 min

Pulmonology

In this ADVENT symposium at the 2024 European Respiratory Society conference, Drs. Sharon Dell and Leonard Bacharier discuss the potential domains of on therapy clinical remission in pediatric severe asthma, emphasizing lung function as a key parameter for children.

IRS-ISIAN 2024 | <b>Remission</b> in CRSwNP: A Real-World Perspective

expert video

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

8 min

Rhinology

Prof. Eugenio De Corso describes the importance of real-world evidence for understanding the prospects of remission and the emerging evidence of biologic effectiveness for patients with CRSwNP.

Current systemic therapies have been shown to induce <b>remission</b> in a subset of AD patients

expert video

Current systemic therapies have been shown to induce remission in a subset of AD patients

5 min

Dermatology

Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.

Podcast

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

23 min

Dermatology

Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.

expert video

Exploring The Concept of Disease Modification in Atopic Dermatitis

13 min

Dermatology

Exploring the concept of disease modification and related pathomechanisms in atopic dermatitis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: JapanChange country/region